Jump to content

BNC-210

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Meodipt (talk | contribs) at 11:17, 15 September 2018. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

BNC-210
Clinical data
ATC code
  • none
Legal status
Legal status
  • Investigational
Identifiers
  • L-Isoleucyl-L-tryptophan
PubChem CID
ChemSpider
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC17H23N3O3
Molar mass317.389 g·mol−1
3D model (JSmol)
  • CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N
  • InChI=1S/C17H23N3O3/c1-3-10(2)15(18)16(21)20-14(17(22)23)8-11-9-19-13-7-5-4-6-12(11)13/h4-7,9-10,14-15,19H,3,8,18H2,1-2H3,(H,20,21)(H,22,23)/t10-,14-,15-/m0/s1
  • Key:BVRPESWOSNFUCJ-LKTVYLICSA-N

BNC210 (also known as IW-2143 during its time licensed to Ironwood Pharmaceuticals) is an anxiolytic drug that acts via negative allosteric modulation of the α7-nicotinic acetylcholine receptor,[1] by Bionomics Limited. It is currently being investigated for the treatment of post traumatic stress disorder.[2] The drug has demonstrated clinically significant anxiety reduction in both animal models and in Phase I trials.[3]

It appears to be devoid of significant sedation or memory-impairing side effects, as well as lacking addictive potential in rat discriminatory models.[4]

Phase I trials have shown no serious side effects.

Bionomics previously licensed it to Ironwood Pharmaceuticals in January 2012, where it was known as IW-2143. In December 2012, IW-2143 begun undergoing phase I clinical trials in the United States,[5] but in November 2014, was released back to Bionomics in a mutual agreement.[6] Bionomics will now continue development and clinical testing, with Ironwood receiving a royalty for their work done.

As of April 2015, BNC210 is in phase II clinical trials.[7] The estimated study completion date is September of 2018. [2]

Study Details

The clinical trial is currently testing twice daily oral dosages of 600 mg, 300 mg, and 150 mg, for 12 weeks. [2] The primary objective of the trial is for the treatment of PTSD with a secondary objective for the effectiveness in treating anxiety disorders and depression. [2]

See also

References

  1. ^ http://www.bionomics.com.au/upload/investors/asx-announcements/4736/ASX695%20%20BNC210%20Phase%201b%20initiation.pdf
  2. ^ a b c d Clinicaltrials.gov. "www.clinicaltrials.gov" (HTML). Clinicaltrials.gov. Retrieved 2018-01-04.
  3. ^ "Bionomics - Pipeline". Retrieved 2010-11-09. Bionomics has discovered a novel compound, BNC210, that offers dramatic competitive advantages over existing treatments
  4. ^ O'Connor, S.; Andriambeloson, E.; Huyard, B.; Wagner, S.; Sleebs, B.; Quasi, N.; Bui, C.; Street, I. "BNC210: A Novel Compound with Potent Anxiolytic Activity" (PDF). Bionomics Limited. Retrieved 2010-11-09. By applying a targeted medicinal chemistry strategy beginning from a compound cited in the literature, Bionomics has developed BNC210
  5. ^ http://investor.ironwoodpharma.com/releasedetail.cfm?ReleaseID=733540
  6. ^ http://www.biotechdaily.com.au/media/backissues/2014/11%20Nov/BD%20Biotech%20Daily%20Nov%2011.pdf
  7. ^ Bionomics Limited. "www.prnewswire.com" (HTML). PRNewswire. Retrieved 2015-06-10.



Stub icon

This article about an anxiolytic is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=BNC-210&oldid=859649398"